PBI premier bionics limited

the answer is here!!!!!

  1. 5,609 Posts.
    Upper Airway Patency Monitoring

    Pulmosonix's technology for monitoring lung inflation is also believe to be applicable to diagnosing and monitoring Obstructive Sleep Apnea (OSA). OSA refers to closure of the upper-airway during sleep. OSA is estimated to effect over 5% of the adult population and has been linked to hypertension, stroke, and heart attack. Pulmosonix's technology could enable the production of a simple take-home diagnostic device for OSA (current diagnosis involves overnight physical examination) as well as a monitoring function to assist in the operation of existing Continuous Positive Airway Pressure (CPAP) devices.

    Market Size : Obstructive Sleep Apnea is estimated to affect over 5% of the adult population. More than 6 million people in the USA have been diagnosed with Obstructive Sleep Apnea and the addressable population for CPAP technology is estimated at over 20 million people. The global market for OSA products is estimated to be $800 million and growing at 20% per annum.

    Route to Market: There are several large companies such as ResMed and Respironics producing CPAP equipment. Pulmosonix's Upper Airway Patency Monitor would likely be an add-on device for existing products and a licensing agreement with one of the major manufacturers is the most likely commercialisation path for this application
watchlist Created with Sketch. Add PBI (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.